Alembic Pharmaceuticals announces acquisition of Utility Therapeutics
Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI).
-Pivya is an FDA approved product to treat uncomplicated UTIs in the US market.
-MEC is a product in development for treatment of the complicated UTIs in the US market.
As a product development company they have minimal turnover in last 3 years.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
a day ago
- Business Standard
Alembic Pharma inks deal to acquire Utility Therapeutics for $12 million
Alembic Pharmaceuticals said that its wholly owned subsidiary Alembic Pharmaceuticals Inc. has acquired Utility Therapeutics for $12 million. Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI). The first product Pivya is an FDA approved product to treat uncomplicated UTIs in the US market. The second product MEC is in development for the treatment of complicated UTIs in the US market. As a product development company they have minimal turnover in last 3 years. Alembic Pharma stated that the acquisition has been made to market the US FDA approved product and under-development product owned by the Utility in USA. The acquisition cost involves a cash component plus profit share out of future profits. The total amount payable is approximately $12 million. The payout would happen in staggered manner over period of time, depending on milestones achieved. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The companys consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24. The scrip advanced 0.95% to currently trade at Rs 999.05 on the BSE.
&w=3840&q=100)
Business Standard
2 days ago
- Business Standard
Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details
Alembic Pharmaceuticals share price rose after the company announced that its wholly-owned subsidiary, Alembic Pharmaceuticals Inc., has acquired Utility Therapeutics Ltd. for approximately $12 mn SI Reporter New Delhi Alembic Pharmaceuticals share price: Pharmaceuticals company Alembic Pharmaceuticals shares were trading higher on Thursday, July 3, 2025, with the scrip rising up to 2.05 per cent to hit an intraday high of ₹1,010 per share. At 11:00 AM, Alembic Pharmaceuticals share price continued to trade higher, up about 1 per cent at ₹998.95. In comparison, BSE Sensex was trading 0.33 per cent higher at 83,688.57 levels. Why did Alembic Pharmaceuticals share price rise today? Alembic Pharmaceuticals share price rose after the company announced that its wholly-owned subsidiary, Alembic Pharmaceuticals Inc., has acquired Utility Therapeutics Ltd. for approximately $12 million. In an exchange filing, Alembic Pharmaceuticals said, 'We are pleased to inform you that Alembic Pharmaceuticals Inc., wholly-owned subsidiary of Alembic Pharmaceuticals Limited, has acquired Utility Therapeutics Ltd.' Utility Therapeutics is a pharmaceutical development company specialising in treatments for urinary tract infections (UTIs). The company is currently working on two key products. The first, Pivya, is already approved by the US Food and Drug Administration (FDA) for the treatment of uncomplicated UTIs in the US market. The second, MEC, is under development and aims to address the treatment of complicated UTIs. As a product development-focused company, Utility Therapeutics has reported minimal turnover over the past three years. Alembic Pharmaceuticals said that the acquisition will be finalised in approximately 30 days. The acquisition will allow the company to market the USFDA approved product and underdevelopment product owned by the Utility in the USA. Track Stock Market LIVE Updates Alembic Pharmaceuticals Q4 results Alembic Pharmaceuticals reported a 12 per cent year-on-year (Y-o-Y) decline in net profit in the March quarter of FY25 (Q4FY25), at ₹157 crore, despite a 17 per cent rise in net sales to ₹1,770 crore. Ebitda grew 9 per cent to ₹286 crore, with the margin at 16 per cent, while profit before tax increased 5 per cent to ₹192 crore. READ MORE About Alembic Pharmaceuticals Alembic Pharmaceuticals is one of India's leading pharmaceutical companies, with a legacy dating back to 1907. Headquartered in Vadodara, Gujarat, the company has established a strong global footprint through its fully integrated operations encompassing research, development, manufacturing, and marketing of pharmaceutical products. A publicly listed entity, Alembic Pharmaceuticals is widely recognised for its extensive portfolio of generic drugs, supported by cutting-edge R&D facilities and approvals from major regulatory bodies, including the USFDA. Its manufacturing facilities are located in Gujarat and Sikkim, while R&D centres in Vadodara, Hyderabad, and New Jersey drive innovation and development. Alembic's global reach is further strengthened by its subsidiaries, Alembic Pharmaceuticals Inc. and Alembic Global Holding SA, positioning the company as a trusted provider of both branded and generic medicines worldwide.
Business Standard
2 days ago
- Business Standard
Alembic Pharmaceuticals announces acquisition of Utility Therapeutics
Alembic Pharmaceuticals Inc., wholly owned subsidiary of Alembic Pharmaceuticals has acquired Utility Therapeutics for a consideration of $12 million in staggered manner over period of time, depending on milestones achieved. Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI). -Pivya is an FDA approved product to treat uncomplicated UTIs in the US market. -MEC is a product in development for treatment of the complicated UTIs in the US market. As a product development company they have minimal turnover in last 3 years.
